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Abstract
Molecular imaging probes can target abnormal gene expression patterns in patients and allow early diagnosis of disease. For
selecting a suitable imaging probe, the current Molecular Imaging and Contrast Agent Database (MICAD) provides descriptive and
qualitative information on imaging probe characteristics and properties. However, MICAD does not support linkage with the
expression profiles of target genes. The proposed Disease-specific Imaging Probe Profiling (DIPP) database quantitatively archives
and presents the gene expression profiles of targets across different diseases, anatomic regions, and subcellular locations, providing
an objective reference for selecting imaging probes. The DIPP database was validated with a clinical positron emission tomography
(PET) study on lung cancer and an in vitro study on neuroendocrine cancer. The retrieved records show that choline kinase beta and
glucose transporters were positively and significantly associated with lung cancer among the targets of 11C-choline and [18F]fluoro-2-
deoxy-2-D-glucose (FDG), respectively. Their significant overexpressions corresponded to the findings that the uptake rate of FDG
increased with tumor size but that of 11C-choline remained constant. Validated with the in vitro study, the expression profiles of
disease-associated targets can indicate the eligibility of patients for clinical trials of the treatment probe. A Web search tool of the
DIPP database is available at http://www.polyu.edu.hk/bmi/dipp/.
I T IS WIDELY ACCEPTED that genes code for proteins,which maintain cellular function and growth. Any
pathologic changes in the gene expression pattern can lead
to cellular malfunction, giving rise to disease. Thus, the
observed change in the gene expression pattern can
provide a sign for early diagnosis and theranosis.
Molecular imaging nowadays provides detailed infor-
mation at the cellular and biochemical levels.1 Such
emerging technology offers biologists and clinicians new
opportunities to noninvasively localize and quantify
certain in vivo molecular events.2–4 Clinically, molecular
imaging has been widely used as a tool for monitoring,
evaluating, and optimizing treatment.5 The existing
molecular imaging techniques include magnetic resonance
imaging (MRI), magnetic resonance spectroscopy (MRS),
ultrasonography, single-photon emission computed tomo-
graphy (SPECT), positron emission tomography (PET),
and, specifically in the preclinical small-animal setting,
optical bioluminescence and fluorescence imaging.6 For
research application, optical imaging has been widely used
for detecting gene expression and protein–ligand interac-
tions in animal studies.1
Molecular imaging probes can interrogate the in vivo
change in regional metabolism of specific pathways in the
body, which are regulated by specific proteins owing to the
fact that the cellular uptake concentration and/or spectral
properties of imaging probes are altered by the specific
biologic process, such as pathologic or physiologic change,
under investigation.7 Therefore, an imaging probe can
respond to the abnormal gene expression pattern with
signals in the patients, and the obtained images facilitate
early diagnosis and more accurate characterization of
disease. Conventional direct binding probes include
positron-emitting analogues of dopamine (e.g., 3-(2-[18F]
fluoroethyl)spiperone, [18F]FESP), which monitor the
dopamine receptors of the striatum, and indirect imaging
probes include hexokinase substrate 2-deoxy-2-[18F]
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fluoro-D-deoxyglucose (FDG), which monitors glucose
metabolism.7
Multimodality imaging, the combined application of
multiple imaging techniques, has been launched to provide
accurate anatomic and functional information simulta-
neously. The combinations include PET/computed tomo-
graphy (CT), which was introduced commercially in 2001,
followed by SPECT/CT in 2004 and PET/MRI in 2008.2
PET/CT acts as an efficient tool for whole-body staging
and restaging within one imaging modality.8 As a result,
multimodal imaging probes become more important for
developing multimodality imaging techniques.2 By admin-
istering new imaging probes with multimodality-imaging
instruments, structural and functional data can be merged
and allow physicians to perform multiple functional imag-
ing assays simultaneously with anatomic analyses.7
Other potential imaging probes are suggested. For
example, Oxygen-15 was proposed for studying regional
cerebral oxygen extraction and metabolism using PET.9
Nanoparticles in nanoplatform-based molecular imaging,
for example, iron oxide nanoparticles as MRI contrast
agents,10 are already available in clinical practice for tumor
targeting and have become more popular due to their
unique properties and multifunctionality in nanoplat-
forms.5 Iron oxide PEGylated (IO-PEG) nanoparticles
have been suggested to serve as an efficient magnetic
resonance contrast agent compared to the commercial
contrast agent Feridex.10 Moreover, the bioconjugated
near-infrared quantum dot probes are recognized as highly
sensitive optical imaging tools for in vivo study.5
Molecular diagnostics, including in vivo imaging of
human bodies and in vitro laboratory test of clinical
samples, involves the use of biologic markers to predict the
risk of developing disease at an early stage. The molecular
phenotype is essential for individualized therapy and
therapeutic monitoring. As a rapidly growing area,
genomics also plays an important role in defining new
direct-imaging targets where gene expression profiling and
proteomic analyses of human tumors have already been
started.8 The approach of reporter gene imaging has been
changed from postmortem tissue sampling and processing
to emphasize noninvasive imaging techniques involving
live animals and human subjects.11 Lifelong reporter gene
imaging in the lungs of mice following polyethyleneimine-
mediated sleeping-beauty transposon delivery is an
example.12
A number of choices of imaging probes with different
specific molecular targets exist. Each imaging method
or probe contributes a unique molecular target profile
characterizing the biologic system.13 Therefore, it is
important to choose an imaging probe whose signal
originates at abnormal cells, which can effectively reflect
the pathologically altered gene expression profile. This goal
can be achieved by integrating the information of the
molecular imaging probes with the genomic and proteo-
mic, morphologic (such as tissue banks), and functional
data of their targets.14 Such an effort facilitates disease-
specific comparison of gene expression patterns among
different imaging methods or probes.
The Molecular Imaging and Contrast Agent Database
(MICAD) provides descriptive and qualitative information
on the characteristics and properties of imaging probes,
such as their molecular targets and the corresponding
gene-disease association.15 However, MICAD could not
provide a systematic, structural, and quantitative data
repository and presentation of the target gene expression
changes associated with particular disease phenotypes. To
address this issue, relevant research effort has been made in
the identification of prognostic imaging biomarkers by
leveraging public gene expression microarray data in non–
small cell lung cancer (NSCLC).16 Such an effort provides
insight for profiling the probes with the molecular context
of the cell. Supported by bioinformatics resources, such as
MetaCore, the Kyoto Encyclopedia of Genes and Genomes
(KEGG), and the Gene Ontology (GO), MICAD was
further extended to establish the Researching Agents
through Molecular Pathways (RAMP) database that
integrates imaging probes with the signaling pathways of
their target genes.17 However, the RAMP database still
lacks the support of the disease-specific quantitative data
of target genes.
An initiative for the development of a systematic and
structural database exists that quantifies the target gene-
disease relationship of every imaging probe. In this study,
it is expected to quantitatively archive and present the
differential gene expression profiles of targets across
different diseases, anatomic regions, and cellular compo-
nents. Such an informatics resource provides a compara-
tive target profiling of various imaging and treatment
probes as an objective and quantitative reference for
supporting the clinical decision and, if the probes have not
yet been tested in humans, piloting the clinical trials.
Methods
Database Design and Construction
The database delivered in this work is called the Disease-
specific Imaging Probe Profiling (DIPP) database. The
DIPP database was constructed by three processes:
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(1) collection of the information of imaging probes and
their corresponding targets; (2) retrieval and processing of
the microarray data sets of specified diseases; and (3) data
integration and identification of significant records.
Processes 1 and 2 were performed in parallel followed by
process 3. Figure 1 shows the flowchart of the database
construction. A Web search tool of the DIPP database is
available at http://www.polyu.edu.hk/bmi/dipp/ and is best
viewed by Firefox or Safari.
Collection of Probe-Target Mappings
The mappings between imaging probes and their targets
were obtained using the export function of a RAMP search
tool (http://www.rampsearch.com/) and manually curat-
ed using MICAD (http://www.ncbi.nlm.nih.gov/books/
NBK5330/).
Each record collected from RAMP provides four
information items: imaging probes, target descriptions,
target official gene symbols, and target subcellular loca-
tions. Although about 4,100 records were collected from
RAMP, some commonly used imaging probes were not
covered. To supplement the inadequacy of the RAMP
database, manual curation of probe-target mappings,
including those for FDG, 11C-choline, 68Ga-DOTATATE,
and 177Lu-DOTATATE, was performed using MICAD. To
identify the targets of those manually curated records
consistently and uniquely, their official symbols and
subcellular locations were obtained from the National
Center for Biotechnology Information (NCBI) and the
Human Protein Atlas (HPA), respectively.18,19
Collection and Processing of Gene Expression Data
In this work, eight diseases, including breast cancer, colon
cancer, NSCLC, head and neck cancer, neuroendocrine
tumor (NET), ovarian cancer, cervical cancer, and
nasopharyngeal carcinoma (NPC), were considered. For
each disease, the related studies were searched and the
corresponding microarray data sets were collected from
the Gene Expression Omnibus (GEO).20 Information
about the region of interest (ROI) was also provided in
the study description in the GEO. The selection criterion
of microarray data sets is the presence of both tumor and
normal subject groups in the studies. Based on this
criterion, microarray data sets of the experiment series,
GSE12452 (NPC), GSE6791 (cervical cancer, head and
neck cancer), GSE43458 (NSCLC), GSE42568 (breast
cancer), GSE26712 (ovarian cancer), and GSE1037
(NET), were retrieved.21–26 All the data sets collected in
the work have already been normalized. According to the
microarray probeset design, a gene may be interrogated by
more than one microarray probe. In this case, the
expression level of the gene is represented by the average
intensity value across the corresponding microarray
probes. For each data set, nonredundant records of targets
were maintained by averaging the multiple microarray
probe intensities.
Multivariate statistical analysis should be applied to
examine the complex interrelationships between the
probes, targets, and diseases. Since a probe may target
multiple genes whose expression levels jointly contribute
to the occurrence of a disease, logistic regression analysis
was performed to identify a linear equation whose output
variable is the logarithm of the odds of a disease and input
variables are the expression levels of target genes. The
coefficient associated with each target gene represents the
log odds ratio (log OR) of the disease with respect to
the expression level of that target gene corrected for the
influence of the others. The p value was also estimated to
determine the significance of the log OR. The positive and
significant log ORs indicate that the corresponding genes
are positively and significantly associated with the disease
and thus contribute to the disease-specific uptake of their
targeting probe.
After the disease-associated genes were identified, their
differential expressions between normal and disease groups
were examined using the Student t-test. Mean expression
levels over control samples (N) and disease samples (T)
were calculated for each record of target. The differ-
ence between T and N was used to indicate whether the
gene was overexpressed or underexpressed in the disease
group.
Data Integration and Identification of Disease-Associated
and Differentially Expressed Genes
Using the database table-joint method, the records of
probe-target mappings and the differential gene expression
parameters obtained from processes 1 and 2 were linked to
form the disease-specific genomic profiling of imaging
probes. The key for joining records is the official gene
symbol. The integrated database records include 11 fields:
imaging probe, target description, official gene symbol,
subcellular locations, disease, ROI, log OR (B), p value of
log OR (pr), mean expression level of normal samples (N),
mean expression level of tumor samples (T), and t-test p
value (pt).
For a particular disease and ROI, each imaging probe
could have k distinct targets. The disease-associated genes
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were identified using the following logistic regression
model:
logit~B0zB1X1zB2X2z . . .zBkXk ð1Þ
where logit is the logarithm of the odds, X1, ..., Xk are the
expression levels of targets and B1, ..., Bk are the
corresponding log ORs. The disease-specific uptake of a
probe can be predicted by its targets, whose expression
levels are positively and significantly associated with the
disease. These positively and significantly associated target
genes (PSATGs) are defined as genes satisfying the criteria
of pr , .05 and B . 0. For each combination of imaging
probes, disease, and ROI, the PSATG records were
identified based on the criteria.
The individual contributions of the PSATGs to the
differential uptake of the probe were further examined
using the Student t-test. To control the type I error of
multiple t-tests of these k database records, Bonferroni
Figure 1. The schematic diagram of the Disease-specific Imaging Probe Profiling (DIPP) database construction: k is the number of targets of an
imaging probe. Logistic regression and t-test were performed to identify disease-associated and differentially expressed targets. Bonferroni
correction, which adjusts the significance level by dividing it by k, was applied to control the type I error of the multiple t-tests. GEO 5 Gene
Expression Omnibus; HPA 5 Human Protein Atlas; MICAD 5 Molecular Imaging and Contrast Agent Database; NCBI 5 National Center for
Biotechnology Information; PSATG 5 positively and significantly associated target gene; RAMP 5 Researching Agents through Molecular
Pathways; SOTG 5 significantly overexpressed target gene.
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correction was applied to adjust the significance level
(a, originally 0.05) for differential gene expression.
Significantly overexpressed target genes (SOTGs) are
defined as genes whose expression profiles satisfy the
criteria of pt , .05/k and T 2 N . 0. The SOTGs were
identified based on the criteria to predict the differential
uptake of the probe comparing the disease to normal cases.
Validation of Database
For a particular disease, we hypothesize that the PSATGs
and SOTGs characterize, respectively, the disease-specific
and the differential uptake properties of an imaging probe
with respect to the disease and the anatomic ROI. To test
this hypothesis, we queried the DIPP database with criteria
corresponding to a clinical PET study.27
In the clinical PET study, the changes in standardized
uptake values (SUVs) against tumor size were compared
between two imaging probes, FDG and 11C-choline, in
lung cancer. The search criteria were ‘‘lung’’ as ROI,
‘‘NSCLC’’ as disease, and ‘‘FDG or 11C-choline’’ as
imaging probes. Such validation mimics the scenario for
comparing the uptake properties of the candidate imaging
probes for molecular imaging.27
As some probes are eligible for treatment, the DIPP
database can also be applied to identify therapeutic
radionuclide and predict its efficacy with respect to the
disease and ROI. To identify potential treatment probes
for NET, we searched for PSATG and SOTG records with
the criteria ‘‘neuroendocrine cancer’’ as disease and ‘‘lung’’
as ROI. The retrieved record was validated by the findings
of an in vitro study on pulmonary NET.28
The Web search tool provides links to the PubMed
webpages of the probes found in the DIPP database. By
clicking on the tracer name of the retrieved records, the
PubMed webpage of the selected probe will be brought out,
showing the excerpt, the background, the synthesis
approach, and the information about the related in vitro
animal and human studies supported by references.
Results
Construction of the DIPP Database
To demonstrate the database construction process, the
information collection from MICAD and HPA corre-
sponding to two commonly used tracers, FDG and 11C-
choline, is illustrated as follows. Table 1 provides the
overview of target-disease relationships identified in
MICAD and HPA. FDG potentially traces 18 targets and
11C-choline 3 targets. The targets include enzymes, trans-
porters, and regulators of metabolic processes. Table 2
shows the detailed information of the relationships, such as
the type, subcellular location, and chromosomal location of
the target. Note that choline transporter was not defined as a
Table 1. Relationships of Target Genes of Two Imaging Probes
with Cancers
Imaging
Probe
Number of Genes
Coding for Target
Proteins
Region of
Associated
Cancer
Number of
Genes Related
FDG 18 Liver 11
Ovarian 11
Carcinoids 10
Colorectal 10
Breast 9
Pancreatic 9
Stomach 9
Testis 9
Lymphoma 9
Endometrial 8
Lung 8
Urothelial 8
Cervical 8
Head and neck 7
Prostate 7
Skin 7
Melanoma 7
Renal 7
Thyroid 6
Glioma 6
11C-Choline 3 Liver 3
Ovarian 3
Carcinoids 3
Stomach 3
Testis 3
Lung 3
Cervical 3
Prostate 3
Melanoma 3
Colorectal 2
Breast 2
Pancreatic 2
Lymphoma 2
Endometrial 2
Urothelial 2
Head and neck 2
Skin 2
Renal 2
Thyroid 2
Glioma 2
FDG 5 [18F]fluoro-2-deoxy-2-D-glucose.
Disease-Specific Target Gene Expression Profiling of Molecular Imaging Probes 5
Table 2. Relationship between Imaging Probes and Target and Related Information Found at MICAD, NCBI, and HPA
Imaging Probe Targets Gene
Subcellular Locations
Main Location Additional Location
[18F]Fluoro-2-
deoxy-2-D-glucose
(FDG)
Hexokinase 1 HK1 Mitochondria Nucleus but not
nucleoli
Hexokinase 2 HK2 Nucleus, cytoplasm Mitochondria
Hexokinase 3 HK3 Cytosol, membrane, mitochondrion,
protein complex
N/A
Glucokinase (hexokinase 4) GCK Cytoplasm, Golgi apparatus N/A
Glucokinase (hexokinase 4)
regulator
GCKRG Cytosol, nucleoplasm N/A
Solute carrier family 2
(facilitated glucose transporter),
member 1
SLC2A1 Basolateral plasma membrane, caveola,
cell–cell junction, female pronucleus,
integral to membrane, melanosome,
membrane, midbody, plasma
membrane
N/A
Solute carrier family 2
(facilitated glucose transporter),
member 2
SLC2A2 Basolateral plasma membrane, brush
border membrane, cytosol, endosome,
integral to plasma membrane,
membrane, plasma membrane
N/A
Solute carrier family 2
(facilitated glucose transporter),
member 3
SLC2A3 Cytoplasm Plasma membrane
Solute carrier family 2
(facilitated glucose transporter),
member 4
SLC2A4 Nucleus but not nucleoli N/A
SLC2A4 regulator SLC2A4
regulator
Cytoplasm, nucleus N/A
Solute carrier family 2
(facilitated glucose transporter),
member 5
SLC2A5 Cytoplasm N/A
Solute carrier family 2
(facilitated glucose transporter),
member 6
SLC2A6 Integral to membrane, membrane,
plasma membrane
N/A
Solute carrier family 2
(facilitated glucose transporter),
member 8
SLC2A8 Vesicles N/A
Solute carrier family 2
(facilitated glucose transporter),
member 9
SLC2A9 Integral to membrane, integral to plasma
membrane, nuclear envelope, plasma
membrane
N/A
Solute carrier family 2
(facilitated glucose transporter),
member 10
SLC2A10 Nucleus but not nucleoli Vesicles
Solute carrier family 2
(facilitated glucose transporter),
member 11
SLC2A11 Integral to membrane, plasma membrane N/A
Solute carrier family 2
(facilitated glucose transporter),
member 12
SLC2A12 Cell junctions Plasma membrane
Solute carrier family 2
(facilitated glucose transporter),
member 13
SLC2A13 Integral to membrane, plasma membrane N/A
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target of 11C-choline at MICAD, but it is important for
incorporating choline into the cell. As such, an extra record
for choline transporter was added to the database.
Validation Results
By setting ‘‘lung’’ as ROI, ‘‘NSCLC’’ as disease, and ‘‘FDG’’
and ‘‘[11C]choline’’ as tracers, we retrieved 13 and 3 target
gene records from the DIPP database for FDG and 11C-
choline, respectively. The records of PSATGs and SOTGs
are shown in Table 3 and Table 4, respectively. Among 3
targets of 11C-choline, choline kinase beta (CHKB) is the
only PSATG that was found to be positively and
significantly associated with NSCLC (log OR 5 3.67,
pr 5 4 3 10
–4) and also the only SOTG that was found to
be significantly overexpressed (pt 5 4.13 3 10
–5 , a/k 5
0.0167) in the microarray data set (GSE43458). Among
13 targets of FDG, solute carrier family 2 member 8
(SLC2A8), which is one of the glucose transporters, and
hexokinase 2 (HK2) were identified as the PSATGs
(log OR 5 9.46, pr 5 .015 and log OR 5 2.72, pr 5
.013, respectively). Four glucose transporters and one
hexokinase were significantly overexpressed among the 13
FDG targets (a/k53.85 3 10–3). The SOTGs are SLC2A2
(p 5 1.42 3 10–4), SLC2A4 (p 5 4.40 3 10–6), SLC2A4RG
(p 5 4.77 3 10–6), SLC2A8 (p 5 8.55 3 10–8), and GCK
(p 5 8.06 3 10–5). SLC2A8 is the only SOTG of the two
PSATGs. For profiling the associations with disease, the
targets were characterized by a panel of two features, y 5
log(OR) and x 5 log(a/pr). For profiling the differential
expression, the targets were characterized by another panel
of two features, y 5 (T 2 N) and x 5 log(a/(pt?k)). The
scatter plots of targets in these two panels of features are
shown in Figure 2 and Figure 3. The first quadrant of the
scatter plots represents the region where the PSATGs and
SOTGs are located.
The identified PSATGs include two enzymes, HK2 and
CHKB, which are targeted by FDG and 11C-choline,
respectively. These two PSATG records justify the similar
disease-associated increase in enzymatic activity and
tumor cell proliferation in lung cancer and support the
baseline disease-specific uptake of these two imaging
probes in clinical PET images.27 However, only SLC2A8
and CHKB were significantly overexpressed among the
three PSATGs. The types of SOTGs targeted by FDG and
11C-choline were so different that the two tracers have
different uptake properties in terms of tumor size. It was
found in the clinical PET study that the SUV of FDG
increased but that of 11C-choline remained unchanged
when tumor size increased. Such a differential uptake
property was characterized by the types of significantly
overexpressed PSATGs that are an enzyme for 11C-choline
and a transporter for FDG.
Imaging Probe Targets Gene
Subcellular Locations
Main Location Additional Location
11C-Choline Choline kinase alpha CHKA Nucleus but not nucleoli N/A
Choline kinase beta CHKB Cytoplasm N/A
Choline transporter* SLC5A7 N/A N/A
HPA 5 Human Protein Atlas; MICAD 5 Molecular Imaging and Contrast Agent Database; N/A 5 not available; NCBI 5 National Center for
Biotechnology Information.
*Information not found at either MICAD or HPA.
Table 2. Continued.
Table 3. DIPP Database Records of PSATGs of 11C-Choline and
FDG in NSCLC
Tracer PSATG Disease Log Odds Ratio pr
11C-Choline CHKB NSCLC 3.67 4.0 3 10–4
FDG SLC2A8 NSCLC 9.46 0.015
FDG HK2 NSCLC 2.72 0.013
DIPP 5 Disease-specific Imaging Probe Profiling; FDG 5 [18F]fluoro-2-
deoxy-2-D-glucose; NSCLC 5 non–small cell lung carcinoma; PSATG 5
positively and significantly associated target gene.
Table 4. DIPP Database Records of SOTGs of 11C-Choline and
FDG in NSCLC
Tracer SOTG Disease T 2 N pt
11C-Choline CHKB NSCLC + 4.13 3 10–5
FDG SLC2A2 NSCLC + 1.42 3 10–4
FDG GCK NSCLC + 8.06 3 10–5
FDG SLC2A4 NSCLC + 4.40 3 10–6
FDG SLC2A4RG NSCLC + 4.77 3 10–6
FDG SLC2A8 NSCLC + 8.55 3 10–8
DIPP 5 Disease-specific Imaging Probe Profiling; FDG 5 [18F]fluoro-2-
deoxy-2-D-glucose; NSCLC 5 non–small cell lung carcinoma; SOTG 5
significantly overexpressed target gene.
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To prove the ability of the DIPP database to identify and
evaluate treatment probes, it was queried for PSATGs and
SOTGs by setting ‘‘neuroendocrine cancer’’ as disease,
‘‘lung’’ as ROI, and ‘‘yes’’ as significantly overexpressed.
Among the 32 retrieved SOTG records, a gene, carbonic
anhydrase IX (CA9), was targeted by a treatment probe,
177Lu-Bn-DTPA-SIP-A3, and its expression level was found
to be associated with neuroendocrine cancer (log OR 5
5.55, pr 5 .01). Labeled with the c- and b-emitting isotope
lutetium 177 with a 6.73-day half-life, the probe is a more
efficient option in radionuclide therapy.29 In the only SOTG
record of a treatment probe for neuroendocrine cancer, the
identified target is CA9. In the in vitro study, the carbonic
anhydrase inhibitor was applied to the lung carcinoid cell
lines, and a significant dose-dependent reduction in cell
viability and colony formation was observed.28 The finding
suggests the application of 177Lu-Bn-DTPA-SIP-A3 to NET,
where CA9 is overexpressed. By clicking on the tracer name
‘‘177Lu-Bn-DTPA-SIP-A3’’ of the retrieved records, its pop-
up PubMed webpage shows a summary of an animal study,
which investigated the tracer biodistribution in mice
bearing colorectal tumors and thus provided important
data supporting further clinical trials.30
Discussion
According to the validation results, the PSATG records of
the DIPP database are able to justify the baseline disease-
specific tracer uptake in PET imaging of cancer. In tumor
cells, an excessive amount of glucose is used to produce
adenosine triphosphate (ATP) through anaerobic glyco-
lysis. The glycolysis is promoted by the increased activity
of glucose transporters and glycolytic enzymes that can
be reflected by a high SUV of FDG. For tumor cell
proliferation, choline is transported into the tumor cells
and then metabolized to phosphatidylcholine, leading to
the cell membrane synthesis. The increased activities of
choline transporter and kinases resulting in the enhanced
cell membrane synthesis can be reflected by a high SUV of
11C-choline. However, the enzymatic activity of tumor
cells is further affected by hypoxia. The blood supply to
the tumor becomes poorer, leading to hypoxia when the
tumor grows. The increase in tumor size further reduces
the molecular oxygen supply and promotes the enzymatic
activity. The significant overexpression of glucose trans-
porters supports this neoplastic metabolic process and
the tumor size–specific differential uptake property of
FDG.27 In contrast, the overexpression of choline kinase
Figure 2. The scatter plot of targets of 11C-choline and FDG with respect to the log odds ratio and its significance of association with non–small
cell lung carcinoma. The points in the first quadrant represent the positively and significantly associated target genes, consisting of HK2, SLC2A8,
and CHKB.
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does not support any tumor size–dependent increase in
11C-choline uptake.27
The validation demonstrated a proof of concept for
using the database as a quantitative reference for predict-
ing the performance of the imaging probes with respect to
particular diseases. In the potential applications of the
DIPP database in clinical practice across all diseases, the
query using a disease and its ROI as the search criteria
corresponds to a list of target gene records. The PSATGs
and SOTGs of the retrieved records, their types, and
involved metabolic processes facilitate the prediction and
comparison of the uptake properties of different imaging
probes under different pathologic conditions, such as
tumor size. Such properties indicate if the imaging probes
fulfill the specific diagnostic and prognostic needs.
Objective selection of tracer is allowed as the PSATGs
and SOTGs provide quantitative evidence.
Apart from the suspected diseases, tracer uptake
depicted unexpectedly in some regions of the molecular
image can be explained by the DIPP database search. By
setting the ROI and imaging probes as the search criteria,
the PSATGs can be identified accordingly, and the
associated diseases provide clinicians with useful informa-
tion for making a differential diagnosis.
The database may also help clinicians identify the
physiologic uptake of the imaging probe at a region other
than the primary region of disease of interest. By setting
ROI and disease as the search criteria, the SOTG records
about other regions, such as the lymph nodes, can provide
useful information for clinicians to differentiate the
physiologic uptakes in metastatic cases from those of the
primary tumors. The current version of the DIPP database
is limited to the ROI, which is the same as the disease
origin. Such function extension will be implemented in the
future version of the DIPP database.
The DIPP database further facilitates the selection
of optimal imaging method among different imaging
modalities. Using disease as a search criterion, the
Figure 3. The scatter plot of targets of 11C-choline and FDG with respect to the mean expression level difference (T 2 N) and its significance of
differential expression in non–small cell lung carcinoma. The points in the first quadrant represent significantly overexpressed target genes,
consisting of GCK, SLC2A2, SLC2A4, SLC2A4RG, SLC2A8, and CHKB.
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intermodality summary of SOTGs can be obtained so that
a better choice of imaging modalities is suggested.
Using the DIPP database, the exploration of disease
mechanism is possible. Since the DIPP database is able to
store detailed information, such as gender, age, source of
tissue, histology, histotype of cancer, type of tumor
(benign, malignant, metastasis), and stage and grade of
cancer in the PSATG records, the corresponding associa-
tion of the gene expression pattern with the disease
progression can be identified for suggesting further
experimental studies on the PSATGs.
The DIPP database potentially explains the interrela-
tionship of target proteins functioning in vivo by tracing
the over- and underexpression patterns of the protein-
coding genes over different disease states. A new hypoth-
esis of a previously unexplained mechanism of proteins in
cellular pathways may be facilitated, gaining momentum
for the flourishing of related pathologic analysis and drug
development.
However, there are a number of concerns regarding the
application of the DIPP database. The MICAD collection
of information of targets will not be further updated after
June 30, 2013. As the imaging probes could target proteins
apart from those listed in the MICAD, such new targets
will be identified, validated, and reported in future
publications. Depending on funding support, periodic
updates of DIPP on the information of targets will be
performed by the scientific editors and curators of our
research team.
Not all of the probes in the MICAD collection have
human studies available. However, the in vitro experi-
ments and animal studies available at the PubMed
webpage, in combination with the disease-specific gene
expression profiling in the DIPP database, provide
supportive data for suggesting further clinical trials of
the probes. In contrast, some imaging probes, such as
FDG and 11C-choline, have been widely used in clinical
applications for the diagnosis, treatment monitoring, and
staging of various diseases, including cancers and central
nervous system disorders. In addition to the related
human studies, the ‘‘Related Resource Links’’ under the
background section of the PubMed webpage provides a
link to ClinicalTrials.gov that lists all of the ongoing and
completed clinical trials of these imaging probes. Although
there are still many ongoing clinical trials of probes,
such as 177Lu-DOTA-TATE (ClinicalTrials.gov Identifier:
NCT01456078), which have not yet been referenced by
MICAD, the scientific editors and curators of our research
team will periodically review and incorporate such findings
into the DIPP database, depending on funding support.
Furthermore, the expression profiling of imaging
probes can be extended to genes coding proteins that
participate in the downstream and upstream of the same
pathways as targets do. The RAMP database does not cover
many such genes involved in the downstream and
upstream of target pathways. For example, the activation
of the phosphatidylinositol 39-kinase(PI3K)-Akt signaling
pathway results in the translocation of glucose transporter
to the cell membrane, facilitating glucose uptake. The
genes involved in such a signaling cascade, such as PI3K
and Akt, are the indirect targets of FDG, and their variants
were found in various cancer types, including ovarian and
colorectal cancers.31 It was also found that the choline
metabolic process interacts with the oncogenic pathways,
such as the RAS pathway and the PI3K-Akt pathway,
where RAS, RAF, and PI3K regulate the enzymatic activity
of choline kinase, and dysregulation was found in breast
and ovarian cancers.32 Thus, RAS, RAF, and PI3K are
indirectly targeted by 11C-choline. If the expression
profiles of these indirect targets of imaging probes can
be further integrated with the DIPP database, a deeper
understanding of the uptake properties of imaging probes
will be possible with the support of the cancer signaling
pathways.
This work also suggests application of the DIPP
database for the identification and evaluation of treatment
probes in diseases, such as neuroendocrine cancer. A
treatment probe, 177Lu-Bn-DTPA-SIP-A3, was identified
through the retrieval of PSATG records in NET. To suggest
the clinical trial of the personalized therapy, the efficacy of
the treatment probe can be evaluated through the
differential expression of PSATGs in the NET biopsy of
the patients who are eligible for such a radionuclide
therapy option.
In this work, the construction of DIPP database was
achieved by data collection, manual curation, integration,
and processing efforts, which were relatively time con-
suming and labor intensive. To continuously extend and
update the database, data integration and update processes
should be computerized and automated.
Conclusion
The DIPP database developed in this study was validated
using a clinical PET study on lung cancer. The hot spots
depicted on the images reflecting the tracer uptake were
verified against the PSATGs and SOTGs in the target gene
records. The tumor size–dependent differential uptake
of FDG was further explained by the fact that the glu-
cose transporters were overexpressed significantly. The
10 Chan et al
validation demonstrated a proof of concept for using the
database as a quantitative reference for predicting the
performance of the imaging and treatment probes with
respect to particular diseases.
Disclaimer
After June 30, 2013, the MICAD website will no longer
provide the new and revised chapters of molecular imaging
probes and contrast agents. The current chapters are still
accessible online at the MICAD website. On the condition
of sufficient future funding support, the research team will
continue to maintain and update the content of the DIPP
database periodically.
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